Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jun;84(11):1453–1459. doi: 10.1054/bjoc.2001.1841

Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours

G Fleischhack 1, S Reif 2, C Hasan 1, U Jaehde 3, S Hettmer 1, U Bode 1
PMCID: PMC2363656  PMID: 11384092

Abstract

As the systemic administration of etoposide is effective in the treatment of relapsed and metastatic brain tumours, a pilot trial was designed to study the feasibility of intraventricular administration of etoposide in such patients. 14 patients aged 2.1 to 33.2 years were treated with intraventricular etoposide simultaneously with either oral or intravenous chemotherapy with trofosfamide or carboplatin and etoposide. In 59 courses (1–12/patient) 0.5 mg etoposide was administered daily via an indwelling subcutaneous reservoir for 5 consecutive days every 2–5 weeks over a period of 0–11 months. During 15 courses in 5 patients serial CSF samples were obtained and etoposide levels were determined by reversed-phase HPLC. Side effects included transient headache and bacterial meningitis, each during 2 courses. Pharmacokinetic data analysis in the CSF (11 courses, 4 patients) revealed a terminal half-life of 7.4±1.2 hours and an AUC of 25.0 ± 9.5 μg h ml–1(mean ± standard deviation). The volume of distribution at steady state and total clearance exhibited a large interindividual variability with mean values of 0.16 l and 0.46 ml min–1respectively. Intraventricularly administered etoposide is well tolerated. CSF peak levels exceed more than 100-fold those achieved with intravenous infusions. Further studies should be focused on optimizing the dose and schedule and on determining the effectiveness of intraventricularly administered etoposide. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: etoposide, intraventricular therapy, metastatic medulloblastoma, pharmacokinetics

Full Text

The Full Text of this article is available as a PDF (74.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berg S. L., Balis F. M., Zimm S., Murphy R. F., Holcenberg J., Sato J., Reaman G., Steinherz P., Gillespie A., Doherty K. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol. 1992 Jan;10(1):143–148. doi: 10.1200/JCO.1992.10.1.143. [DOI] [PubMed] [Google Scholar]
  2. Bergman I., Pohl C. R., Venkataramanan R., Burckart G. J., Stabin M., Barmada M. A., Griffin J. A., Cheung N. K. Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats. J Immunother. 1999 Mar;22(2):114–123. doi: 10.1097/00002371-199903000-00003. [DOI] [PubMed] [Google Scholar]
  3. Blaney S. M., Balis F. M., Poplack D. G. Current pharmacological treatment approaches to central nervous system leukaemia. Drugs. 1991 May;41(5):702–716. doi: 10.2165/00003495-199141050-00003. [DOI] [PubMed] [Google Scholar]
  4. Blaney S. M., Balis F. M., Poplack D. G. Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Williston Park) 1991 May;5(5):107-16; discussion 123, 127. [PubMed] [Google Scholar]
  5. Blaney S. M., Cole D. E., Godwin K., Sung C., Poplack D. G., Balis F. M. Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol. 1995;36(2):121–124. doi: 10.1007/BF00689195. [DOI] [PubMed] [Google Scholar]
  6. Blasberg R. G., Patlak C., Fenstermacher J. D. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther. 1975 Oct;195(1):73–83. [PubMed] [Google Scholar]
  7. Chamberlain M. C., Khatibi S., Kim J. C., Howell S. B., Chatelut E., Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol. 1993 Mar;50(3):261–264. doi: 10.1001/archneur.1993.00540030027009. [DOI] [PubMed] [Google Scholar]
  8. Chamberlain M. C., Kormanik P. A., Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg. 1997 Nov;87(5):694–699. doi: 10.3171/jns.1997.87.5.0694. [DOI] [PubMed] [Google Scholar]
  9. Chamberlain M. C., Kormanik P., Jaeckle K. A., Glantz M. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology. 1999 Jan 1;52(1):216–217. doi: 10.1212/wnl.52.1.214-b. [DOI] [PubMed] [Google Scholar]
  10. Dunkel I. J., Boyett J. M., Yates A., Rosenblum M., Garvin J. H., Jr, Bostrom B. C., Goldman S., Sender L. S., Gardner S. L., Li H. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol. 1998 Jan;16(1):222–228. doi: 10.1200/JCO.1998.16.1.222. [DOI] [PubMed] [Google Scholar]
  11. Farina P., Marzillo G., D'Incalci M. High-performance liquid chromatography determination of 4'-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma. J Chromatogr. 1981 Jan 2;222(1):141–145. doi: 10.1016/s0378-4347(00)81044-0. [DOI] [PubMed] [Google Scholar]
  12. Grossman S. A., Krabak M. J. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999 Apr;25(2):103–119. doi: 10.1053/ctrv.1999.0119. [DOI] [PubMed] [Google Scholar]
  13. Hande K. R., Wedlund P. J., Noone R. M., Wilkinson G. R., Greco F. A., Wolff S. N. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res. 1984 Jan;44(1):379–382. [PubMed] [Google Scholar]
  14. Henwood J. M., Brogden R. N. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs. 1990 Mar;39(3):438–490. doi: 10.2165/00003495-199039030-00008. [DOI] [PubMed] [Google Scholar]
  15. Kiya K., Uozumi T., Ogasawara H., Sugiyama K., Hotta T., Mikami T., Kurisu K. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol. 1992;29(5):339–342. doi: 10.1007/BF00686001. [DOI] [PubMed] [Google Scholar]
  16. Kleihues P., Burger P. C., Scheithauer B. W. The new WHO classification of brain tumours. Brain Pathol. 1993 Jul;3(3):255–268. doi: 10.1111/j.1750-3639.1993.tb00752.x. [DOI] [PubMed] [Google Scholar]
  17. Kühl J., Müller H. L., Berthold F., Kortmann R. D., Deinlein F., Maass E., Graf N., Gnekow A., Scheurlen W., Göbel U. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89. Klin Padiatr. 1998 Jul-Aug;210(4):227–233. doi: 10.1055/s-2008-1043883. [DOI] [PubMed] [Google Scholar]
  18. Nakagawa H., Yamada M., Fukushima M., Ikenaka K. Intrathecal 5-fluoro-2'-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study. Cancer Chemother Pharmacol. 1999;43(3):247–256. doi: 10.1007/s002800050891. [DOI] [PubMed] [Google Scholar]
  19. Postmus P. E., Holthuis J. J., Haaxma-Reiche H., Mulder N. H., Vencken L. M., van Oort W. J., Sleijfer D. T., Sluiter H. J. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration. J Clin Oncol. 1984 Mar;2(3):215–220. doi: 10.1200/JCO.1984.2.3.215. [DOI] [PubMed] [Google Scholar]
  20. Relling M. V., Mahmoud H. H., Pui C. H., Sandlund J. T., Rivera G. K., Ribeiro R. C., Crist W. M., Evans W. E. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Feb;14(2):399–404. doi: 10.1200/JCO.1996.14.2.399. [DOI] [PubMed] [Google Scholar]
  21. Rubinstein L. J., Herman M. M., Long T. F., Wilbur J. R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer. 1975 Feb;35(2):291–305. doi: 10.1002/1097-0142(197502)35:2<291::aid-cncr2820350202>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  22. Sampson J. H., Archer G. E., Villavicencio A. T., McLendon R. E., Friedman A. H., Bishop W. R., Bigner D. D., Friedman H. S. Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res. 1999 May;5(5):1183–1188. [PubMed] [Google Scholar]
  23. Savaraj N., Feun L. G., Lu K., Gray K., Wang C., Loo T. L. Pharmacology of intrathecal VP-16-213 in dogs. J Neurooncol. 1992 Jul;13(3):211–215. doi: 10.1007/BF00172472. [DOI] [PubMed] [Google Scholar]
  24. Schmandt S., Kühl J. Chemotherapy as prophylaxis and treatment of meningosis in children less than 3 years of age with medulloblastoma. J Neurooncol. 1998 Jun-Jul;38(2-3):187–192. doi: 10.1023/a:1005924017460. [DOI] [PubMed] [Google Scholar]
  25. Slavc I., Schuller E., Czech T., Hainfellner J. A., Seidl R., Dieckmann K. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol. 1998 Jun-Jul;38(2-3):213–218. doi: 10.1023/a:1005940405165. [DOI] [PubMed] [Google Scholar]
  26. Stremetzne S., Jaehde U., Schunack W. Determination of the cytotoxic catechol metabolite of etoposide (3'O-demethyletoposide) in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997 Dec 5;703(1-2):209–215. doi: 10.1016/s0378-4347(97)00410-6. [DOI] [PubMed] [Google Scholar]
  27. Tomlinson F. H., Lihou M. G., Smith P. J. Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas. Br J Cancer. 1991 Dec;64(6):1051–1059. doi: 10.1038/bjc.1991.464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. van der Gaast A., Sonneveld P., Mans D. R., Splinter T. A. Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Cancer Chemother Pharmacol. 1992;29(4):335–337. doi: 10.1007/BF00685957. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES